Rim S Ishak

American University of Beirut, Beyrouth, Beyrouth, Lebanon

Are you Rim S Ishak?

Claim your profile

Publications (13)47.38 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Sarcoidosis is a multi-system granulomatous disease of unknown etiology. The skin is involved in 25% of cases. Studies on cutaneous sarcoidosis from our region are lacking.Objectives This study was conducted to describe clinical and histopathologic findings in all patients diagnosed with cutaneous sarcoidosis at the American University of Beirut Medical Center between 1992 and 2010 and to compare findings with those published in the literature.Methods Clinical charts of patients with cutaneous sarcoidosis were retrospectively reviewed. Extracutaneous lesions were classified by organ involvement. Treatment was documented. Pathology specimens were reviewed.ResultsCutaneous sarcoidosis was diagnosed in 76 Lebanese patients, 79% of whom were women. Mean age at diagnosis was 48 years. A total of 29% of patients had systemic disease that was commonly associated with lupus pernio lesions and subcutaneous sarcoidosis. The most common cutaneous lesions were sarcoidal plaques. The histopathologic features in our series did not differ from those described in the literature, except for the documented presence of a grenz zone. Interestingly, 23% of biopsy specimens contained perineural granulomas, raising the possibility of tuberculoid or borderline tuberculoid leprosy. Foreign bodies were detected in 10% of cases (all had systemic involvement), supporting the opinion that sarcoidosis and granulomatous foreign body reaction are not mutually exclusive.Conclusions The clinical and histopathologic features of cutaneous sarcoidosis patients in the present series are generally comparable with those published in the literature, with minor differences. Clinically, the most commonly seen lesion was plaque. Microscopically, cutaneous sarcoidosis may exhibit a grenz zone and may show perineural inflammation and foreign bodies.
    International journal of dermatology 09/2014; · 1.18 Impact Factor
  • Rim S. Ishak, Mazen Kurban, Ossama Abbas
    Pediatric Dermatology 03/2014; 31(2). · 1.04 Impact Factor
  • Rim S Ishak, Ossama Abbas
    [Show abstract] [Hide abstract]
    ABSTRACT: The 8-year-old boy was otherwise healthy. So what was causing these painful lesions to erupt on his hand?
    The Journal of family practice 01/2014; 63(1):33-5. · 0.67 Impact Factor
  • Rim S Ishak, Melissa P Piliang
    [Show abstract] [Hide abstract]
    ABSTRACT: Although the association between alopecia areata (AA), psoriasis, and other autoimmune diseases has been well reported in the literature, an association with metabolic syndrome has not been reported. We present two young women with the combination of severe psoriasis, androgen excess, metabolic syndrome, thyroiditis, and AA. Both women ultimately progressed to treatment-resistant alopecia universalis. This constellation of autoimmunity and metabolic syndrome presents a therapeutic challenge while highlighting the need for full laboratory assessment of AA patients. Careful selection of biological treatment regimens may offer therapeutic benefit for both their psoriasis and AA while giving us experience with the newer biologics in AA.
    Journal of Investigative Dermatology Symposium Proceedings 12/2013; 16(1):S56-7. · 3.73 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The role of the VEGF signaling pathway in angiogenesis has been extensively investigated, and many new targeted anti-angiogenic drugs have evolved from this knowledge. The recent approval and introduction of these anti-neoplastic drugs has revolutionized the treatment of many types of cancers, but has also revealed numerous toxicities to the skin and its adnexae. Since these cutaneous side effects may have a significant impact on the physical, emotional and psychosocial health of patients, it is important for dermatologists and oncologists alike to be aware of the cutaneous complications of these drugs in order to properly diagnose and treat them. This review will detail the presentation of the cutaneous complications of the anti-angiogenic drugs, most notably bevacizumab, sorafenib and sunitinib, and shed light on the management of such adverse reactions.
    Critical reviews in oncology/hematology 12/2013; · 5.27 Impact Factor
  • Source
    Turkish Journal of Haematology 06/2013; 30(2):184-7. · 0.49 Impact Factor
  • Rim Ishak, Ossama Abbas
    [Show abstract] [Hide abstract]
    ABSTRACT: Penicillamine is a well-known heavy metal chelator, classically used in the treatment of Wilson disease, rheumatoid arthritis, and cystinuria. From a dermatologic standpoint, penicillamine was found to be useful in the treatment of systemic sclerosis. The successful therapeutic uses of penicillamine have been hindered by its numerous adverse effects, both cutaneous and extra-cutaneous. It is a unique drug since it provokes a diversity of dermatologic manifestations that include (1) acute hypersensitivity reactions, (2) dermopathies characterized by elastic fiber abnormalities including elastosis perforans serpiginosa and pseudo-pseudoxanthoma elasticum, (3) autoimmune disorders such as pemphigus and penicillamine-induced lupus erythematosus-like syndrome, and (4) miscellaneous dermatoses that result from undefined mechanisms. These cutaneous adverse effects may correlate with the dosage and duration of penicillamine therapy as well as the disease being treated.
    American Journal of Clinical Dermatology 04/2013; · 2.52 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Livedoid vasculopathy is characterized by painful purpuric lesions on the extremities which frequently ulcerate and heal with atrophic scarring. For many years, livedoid vasculopathy has been considered to be a primary vasculitic process. However, there has been evidence considering livedoid vasculopathy as an occlusive vasculopathy due to a hypercoagulable state. We present the case of livedoid vasculopathy in a 21-year-old female who had been suffering of painful lower extremity lesions of 3 years duration. The patient was found to be lupus anticoagulant positive and homozygous for methylenetetrahydrofolate reductase C677T mutation. The patient was successfully treated with low-molecular-weight heparin.
    Journal of Thrombosis and Thrombolysis 05/2012; 34(4):541-4. · 1.99 Impact Factor
  • Archives of dermatology 05/2012; 148(5):641-6. · 4.76 Impact Factor
  • Journal of Clinical Oncology 03/2012; 30(7):e88-90. · 18.04 Impact Factor
  • Rami Abadi, Rim Ishak, Ossama Abbas
    International journal of dermatology 12/2011; 50(12):1465-6. · 1.18 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Renal venous thrombosis (RVT) is a rare but a well recognized entity in children and neonates. The clinical signs of neonatal RVT include hypertension, enlarged kidney(s), hematuria, renal insufficiency, proteinuria, thrombocytopenia, or all. Persisting impairment of kidney function and hypertension are serious and common complications in patients with RVT. Risk factors for the development of RVT include maternal diabetes mellitus, pathologic states associated with thrombosis (e.g., shock, dehydration, perinatal asphyxia, polycythemia), and sepsis. Inherited prothrombotic abnormalities have been described in some reports of RVT. We report the case of a male newborn with left RVT and associated homozygosity for both factor V Leiden (G1691A) and methylenetetrahydrofolate reductase C677T mutations in addition to elevated serum lipoprotein (a). The patient was treated with heparin. We believe our case to be the first reported case in the English medical literature of such an association between neonatal RVT and homozygosity for both factor V Leiden and methylenetetrahydrofolate reductase. This case and other studies clearly demonstrate that neonatal RVT should be evaluated for thrombophilia conditions.
    Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis 07/2009; 20(6):458-60. · 1.25 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Tumor hypoxia is a common feature of many cancers. A master regulator of hypoxic response is the transcription factor hypoxia-inducible factor-1 (HIF-1). It functions as a master regulator of oxygen and undergoes conformational changes in response to varying oxygen concentrations. In this paper, we review what has been described about HIF-1: its structure, its regulation and target genes, its role in cancer, and its implication for cancer therapy.
    Critical reviews in oncology/hematology 02/2009; 70(2):93-102. · 5.27 Impact Factor